Status: Recruiting
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Participants needed: 60
Trial details
Phase: Phase 2Age: 40-85Biological sex: AllType: InterventionalSponsor: CytokineticsUpdated: Aug 27, 2026Locations: 26
Eligibility criteria
Males and females ≥ 40 years and ≤ 85 years of age at screening. [+6]
History or evidence of any other clinically significant disorder, malignancy, ac... [+1]